These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37854677)

  • 1. Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.
    Hsu PC; Huang CY; Lin YC; Lee SH; Chiu LC; Wu CE; Kuo SC; Ju JS; Huang AC; Ko HW; Wang CC; Yang CT
    Front Oncol; 2023; 13():1249106. PubMed ID: 37854677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
    Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell 
Lung Cancer Patients with Acquired EGFR T790M Mutation].
    Gu Y; Tian X; Wang R; Li X; Qian K; Li Y; Nong J
    Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):843-851. PubMed ID: 36617470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
    Poh ME; Balakrishnan S; Tan SN; Zainal Abidin MA; Liam CK; Tan JL; Pang YK; Alaga A; Tho LM; How SH
    Transl Lung Cancer Res; 2024 Jul; 13(7):1649-1659. PubMed ID: 39118879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
    Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
    Thorac Cancer; 2022 Jul; 13(13):1888-1897. PubMed ID: 35633141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
    Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
    Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
    Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
    Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
    Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
    Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
    Front Oncol; 2022; 12():863666. PubMed ID: 35785185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
    Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
    Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in
    Haratake N; Misumi T; Yamanaka T; Seto T
    JTO Clin Res Rep; 2020 Nov; 1(4):100085. PubMed ID: 34589964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study.
    Lee SH; Lin YC; Chiu LC; Ju JS; Tung PH; Huang AC; Li SH; Fang YF; Chen CH; Kuo SC; Wang CC; Yang CT; Hsu PC
    Ther Adv Med Oncol; 2022; 14():17588359221113278. PubMed ID: 35898964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs.
    Ninomaru T; Hata A; Kokan C; Okada H; Tomimatsu H; Ishida J
    Thorac Cancer; 2021 Mar; 12(6):746-751. PubMed ID: 33475261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.